Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Doximity runs a social network and software tools for doctors, and makes money by selling advertising and hiring services to drugmakers and hospitals.
Doximity is a professional network built just for doctors and other healthcare workers. Think of it as LinkedIn for physicians: a place where a doctor can set up a profile, reconnect with colleagues from medical school, read news about their specialty, and look up information about drugs. Millions of verified medical professionals use it, and that audience is the whole business.
The company sells access to that audience. Drugmakers want to reach doctors with information about new medicines, and they pay Doximity to run ads and send targeted messages that land in front of the right physicians. Hospitals and recruiting firms pay to post jobs, since Doximity is a natural place to find doctors looking for their next role. There is also a paid subscription tier called Doximity GPT, which bundles AI tools that help doctors draft paperwork, letters, and other writing. That AI product is a newer bet and a small slice of revenue so far, but it shows where the company is trying to grow beyond advertising. The appeal to customers is precision. Instead of blanketing the internet with ads and hoping a doctor notices, a drugmaker can pay Doximity to reach, say, oncologists in a specific region. Doctors come for the free tools and the colleague network, and the drugmakers pay for the access. That mismatch — free for users, paid for by advertisers — is the classic media business model, and it works because Doximity's user base is verified and hard to replicate.
The business is small in headcount but very profitable, and it throws off a lot of cash. Management has used that cash partly to buy back its own shares, which shrinks the share count and lifts per-share results. The main risk is dependence on drug advertising budgets: when pharma marketing spending slows, Doximity feels it. Its challenge is keeping doctors engaged and turning new products like the AI tools into a second real revenue stream, so the company is not just a toll booth on pharma ad dollars.
Saved answer · last researched 20 Oct 2026